New Biomarker for Castration-Resistant Prostate Cancer: A Glycobiological Perspective
Cancer-associated glycan aberrations are frequently observed in tumors. Glycan alterations are reported to have potential as cancer biomarkers. An aberrant glycosylation and glycosyl epitope have been known to be tumor-associated antigens. In addition, changes in glycosyltransferase could be associated with the signal pathways. Detecting in aberrant glycosylation on prostate-specific antigen (α2,3-linked sialylation) may improve specificity in detection of prostate cancer. However, a practical procedure to analyze a large number of glycan samples quickly is not available for serum due to methodological problems. Recent progress in mass spectrometry has led to new challenges in glycan analysis including a chemo-selective glycan enrichment technology called glycoblotting to purify oligosaccharides from a crude glycoprotein mixture. Previous study suggested that triand tetra-antennary N-glycans were significantly higher in CRPC patients than in non-CRPC patients, and the expression of N-glycan branching enzyme genes was significantly upregulated in CRPC cell lines. These results suggest that the overexpression of triand tetra-antennary N-glycans may be associated with the castration-resistant status in prostate cancer and may be a potential predictive biomarker for CRPC. The incorporation of glycan biomarkers appears to be a promising approach for improving CRPC detection.
KeywordsProstate cancer Castration-resistant prostate cancer N-glycan Glycobiology
This work was supported by a Grant-in-Aid for Scientific Research (No. 15H02563 15 K15579, 17 K11118, 17 K11119, 17 K16768, 17 K16770, and 17 K16771) from the Japan Society for the Promotion of Science.
- 3.Kyan A, Kamimura N, Hagisawa S, Hatakeyama S, Koie T, Yoneyama T, et al. Positive expressions of N-acetylglucosaminyltransferase-V (GnT-V) and beta1-6 branching N-linked oligosaccharides in human testicular germ cells diminish during malignant transformation and progression. Int J Oncol. 2008;32(1):129–34.PubMedGoogle Scholar
- 5.Sato T, Yoneyama T, Tobisawa Y, Hatakeyama S, Yamamoto H, Kojima Y, et al. Core 2 beta-1, 6-N-acetylglucosaminyltransferase-1 expression in prostate biopsy specimen is an indicator of prostate cancer aggressiveness. Biochem Biophys Res Commun. 2016;470(1):150–6. https://doi.org/10.1016/j.bbrc.2016.01.011.CrossRefPubMedGoogle Scholar
- 8.Oikawa M, Hatakeyama S, Narita T, Yoneyama T, Tobisawa Y, Yamamoto H, et al. Significance of serum N-glycan profiling as a diagnostic biomarker in urothelial carcinoma. Eur Urol Focus. 2017. https://doi.org/10.1016/j.euf.2016.11.004.
- 10.Furukawa J, Shinohara Y, Kuramoto H, Miura Y, Shimaoka H, Kurogochi M, et al. Comprehensive approach to structural and functional glycomics based on chemoselective glycoblotting and sequential tag conversion. Anal Chem. 2008;80(4):1094–101. https://doi.org/10.1021/ac702124d.CrossRefPubMedGoogle Scholar
- 14.Lee SH, Hatakeyama S, Yu SY, Bao X, Ohyama C, Khoo KH, et al. Core3 O-glycan synthase suppresses tumor formation and metastasis of prostate carcinoma PC3 and LNCaP cells through down-regulation of alpha2beta1 integrin complex. J Biol Chem. 2009;284(25):17157–69. https://doi.org/10.1074/jbc.M109.010934.CrossRefPubMedPubMedCentralGoogle Scholar
- 17.Ohyama C, Hosono M, Nitta K, Oh-eda M, Yoshikawa K, Habuchi T, et al. Carbohydrate structure and differential binding of prostate specific antigen to Maackia Amurensis lectin between prostate cancer and benign prostate hypertrophy. Glycobiology. 2004;14(8):671–9. https://doi.org/10.1093/glycob/cwh071.CrossRefPubMedGoogle Scholar
- 18.Tsuchiya N, Ohyama C, Habuchi T. Tumor markers in prostate cancer—clinical significance and future prospect of prostate specific antigen (PSA). Gan To Kagaku Ryoho. 2005;32(2):275–80.Google Scholar
- 20.Yoneyama T, Ohyama C, Hatakeyama S, Narita S, Habuchi T, Koie T, et al. Measurement of aberrant glycosylation of prostate specific antigen can improve specificity in early detection of prostate cancer. Biochem Biophys Res Commun. 2014;448(4):390–6. https://doi.org/10.1016/j.bbrc.2014.04.107.CrossRefPubMedGoogle Scholar
- 21.Ishikawa T, Yoneyama T, Tobisawa Y, Hatakeyama S, Kurosawa T, Nakamura K, et al. An automated micro-total immunoassay system for measuring cancer-associated alpha2,3-linked Sialyl N-Glycan-carrying prostate-specific antigen may improve the accuracy of prostate cancer diagnosis. Int J Mol Sci. 2017;18(2):E470. https://doi.org/10.3390/ijms18020470.CrossRefPubMedGoogle Scholar
- 22.Nishimura S, Niikura K, Kurogochi M, Matsushita T, Fumoto M, Hinou H, et al. High-throughput protein glycomics: combined use of chemoselective glycoblotting and MALDI-TOF/TOF mass spectrometry. Angew Chem Int Ed Engl. 2004;44(1):91–6. https://doi.org/10.1002/anie.200461685.CrossRefPubMedGoogle Scholar